Jiangsu Academy of Clinical and Translational Research
Jiangsu Academy of Clinical and Translational Research was established in 2009 with approval from Jiangsu provincial government, relying on the province's most competitive hospital in general capacity, ie. the First Affiliated Hospital with Nanjing Medical Unversity, Jiangsu Provincial Hospital. The Academy has three functional platforms including, the Basic Research and Innovation Platform, Clinical Research and Translational Medicine Platform and the Industrialization Transformation Center.
Jiangsu Academy of Clinical and Translational Research adheres to the concept of promotion of basic study and clinical research, with integration of basic research and clinical research resources from the hospital, strengthen substantive cooperation with other scientific research institutions, to establish a multi-disciplinary, multi-technology integration of clinical research platform, to speed up the innovative technology and basic medical research results to the clinical application, to improve the province's capacity in scientific innovation and technological advancement in the medicine, and ultimately promote the development of health and pharmaceutical industry in Jiangsu.
Basic Research and Innovation Platform
The Basic Research and Innovation Platform was established around Xianzhi Building, which has a total construction area of 21,363 square meters. The platform includes a series of basic research departments including five research institutes of cardiopulmonary disease, tumor, organ transplantation and immunization, allergic diseases, and liver surgery, as well as stem cell and tissue regeneration center, and common experimental platform and clinical resource biobank. The common research platform has the capability in basic experiments, microscopic characterization detection, cell function testing, genetic testing, pathological analysis and so on. With the support from Major Project of Jiangsu Provincial Department of Science and Technology, our hospital is taking the leading role in construction of " Jiangsu Biobank of Clinical Resources ". With the pancreatic disease biobank in the hospital as pioneer, the biobank in the hospital has facilities covering an area of about 680 square meters, standardized work system, and consistent with international general norms, with the hope to build a high level standard clinical resources and information Biobank. With advanced technologies, we aim to provide high level scientific research services for researchers in the province, sharing research resources, hope to offer all-round service in scientific and technological innovation, and ultimately enhance the level of medical technology in Jiangsu Province.
Clinical Research and Translational Medicine Platform
The Clinical Research and Translational Medicine Platform is mainly relying on the national drug clinical trial institutions. Drug clinical trial institutions is one of the earliest established national drug clinical trial organizations, which is founded in 1983. Twenty-eight clinical disciplines have been approved by CFDA, including infection, cardiovascular, endocrine, respiratory, maternity, neurology, skin, blood, medical imaging (diagnosis), Urinary, digestive, otorhinolaryngology, orthopedics, rehabilitation medicine (trauma), general surgery, geriatric (senile dementia), rheumatism, kidney, tumor, pediatric endocrine, pediatric anti-infection, oral, anesthesia, digestive ophthalmology , Nuclear medicine, chest, burn plastic surgery professional. The institution has a Phase I clinical trial laboratory, which covers an area of 900 square meters, with 25 beds. The capacity for supplying clinical research service ranked sixth in China (from CFDA-CDE clinical trial registration and information disclosure platform in 2015). In the past five years, the institution has undertaken clinical trials for 265 new drugs and 79 medical devices, and Phase I trials for 10 new drugs of 1.1 class. The hospital Human Subjects Protection Program was accredited by Association for the Accreditation of Human Research Protection Program (AAHRPP) and the hospital IRB was recognized by WHO/ SICER, both ensure interantional level of human subjects protection in research. The Academy has further established a highly structured and intelligent clinical research database, formed a collaborative research network covering the whole province, and built an electronic data collection system that can realize the sharing of information between hospitals, and thus formed a high level Clinical Research and Translational Medicine Platform, providing support for medical research and innovation and development in the province.
Industrialization Transformation Center
In recent years, the Academy has gradually established a mechanism and platform for the transformation of research results to clinical use, which is conducive to the transformation of academic achievements to the reputation, efficiency and core competitiveness of clinical discipline, and created favorable environmental conditions for the transformation of scientific and technological achievements. The hospital has formulated the translations regulations and other policies, improve the incentives measures, focusing on supporting scientific and technical personnel to Jiangning Science Park to founded their science and technology enterprises, and guide them to establish a strong sense of transformation and entrepreneurial awareness, to speed up the realization of technology and capital, and has cooperation in key technology research and development and product industrialization, sharing research results and benefits, thus forming a Jiangning Science Park as the mainstay of the industrial industrialization Transformation Center.